The ongoing phase II EMERGING trial is comparing neoadjuvant erlotinib to cisplatin-gemcitabine in patients with stage IIIA EGFR-mutant NSCLC (NCT01407822). Here, EGFR is linked to non-small cell lung carcinoma.